How to Get Fosamax (Alendronate) in Montana

Prescription access and medication affordability image for How to Get Fosamax (Alendronate) in Montana

At a glance

  • Drug / alendronate (brand: Fosamax), oral bisphosphonate for osteoporosis
  • Standard dose / 70 mg tablet taken once weekly on an empty stomach
  • Prescribers allowed / MDs, DOs, NPs, PAs all licensed to prescribe in Montana
  • Telehealth legal / yes, Montana law permits remote prescribing after a valid patient-provider relationship is established
  • Key labs before prescribing / DEXA scan T-score, serum creatinine, serum calcium, 25-OH vitamin D
  • Montana Medicaid coverage / not currently covered for osteoporosis indication
  • FIT trial fracture reduction / alendronate cut vertebral fracture risk by 47% vs. placebo over 3 years (N=2,027)
  • Typical time to first dose / 3 to 7 business days for telehealth consult plus pharmacy fill

What Is Alendronate and Why Montana Patients Need It

Alendronate is a nitrogen-containing bisphosphonate that reduces bone resorption by inhibiting osteoclast activity, preserving bone mineral density and lowering fracture risk. The FDA first approved Fosamax for postmenopausal osteoporosis in 1995, and generic alendronate has been available since 2008, making cost a smaller barrier than it once was. FDA Fosamax label

Montana has a population density of roughly 7 people per square mile, the fourth-lowest in the country. For many residents, the nearest endocrinologist or rheumatologist sits 90 to 150 miles away. Telehealth prescribing fills that gap legally and efficiently, as Montana's telehealth statute (Montana Code Annotated 37-3-342) permits prescription of non-controlled medications after a synchronous audio-video visit that meets the standard of care. Women over 65 and men over 70 face the highest osteoporosis risk, and delayed treatment translates directly into preventable hip and vertebral fractures.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), showed that alendronate reduced the risk of new vertebral fractures by 47% and hip fractures by 51% versus placebo over 36 months in women with existing vertebral fractures. FIT trial, JAMA 1998 Those numbers represent real lives and real independence, especially for rural Montanans who cannot afford a fall that takes them off a ranch or out of a home they manage alone.

Who Can Prescribe Alendronate in Montana

Any licensed prescriber in Montana can write for alendronate. Full prescriptive authority in the state extends to:

  • Medical doctors (MDs) and doctors of osteopathic medicine (DOs): Unrestricted prescriptive authority.
  • Nurse practitioners (NPs): Montana NPs operate under full practice authority per Montana Code Annotated 37-8-202, meaning they prescribe independently without a collaborating physician agreement.
  • Physician assistants (PAs): Prescribe under a delegation agreement with a supervising physician, which most Montana PA practices already maintain.

Primary care providers write the large majority of bisphosphonate prescriptions nationally. A 2022 analysis in the Journal of Bone and Mineral Research found that fewer than 20% of osteoporosis prescriptions originate from specialists. JBMR 2022 via PubMed Your family medicine doctor in Billings or a telehealth NP practicing under Montana licensure can prescribe this medication on your first qualifying visit.

The HealthRX clinical team uses a three-gate framework before issuing an alendronate prescription:

  1. Gate 1: Indication confirmed. T-score of -2.5 or below at lumbar spine, femoral neck, or total hip on DEXA, OR a T-score between -1.0 and -2.5 with a FRAX 10-year major osteoporotic fracture probability at or above 20%, OR a prior fragility fracture regardless of T-score.
  2. Gate 2: Contraindications excluded. Estimated GFR must be at or above 35 mL/min/1.73m² (alendronate is not recommended when GFR <35). Esophageal abnormalities, inability to sit upright for 30 minutes, and uncorrected hypocalcemia are absolute contraindications.
  3. Gate 3: Calcium and vitamin D adequacy addressed. Prescribers confirm dietary calcium intake or co-prescribe supplementation, and correct 25-OH vitamin D deficiency before or concurrent with starting alendronate.

Labs Required Before Getting a Fosamax Prescription in Montana

Labs are not optional. They protect you and they protect your prescriber. Most telehealth platforms accept results from any CLIA-certified laboratory, including LabCorp, Quest Diagnostics, and local Critical Access Hospital labs throughout Montana.

Required labs:

  • Serum calcium (corrected for albumin)
  • Serum creatinine with estimated GFR calculation
  • 25-hydroxyvitamin D
  • DEXA scan report with T-scores at lumbar spine and hip (if not done in the prior 24 months)

Often recommended:

  • Complete metabolic panel
  • PTH (intact) if calcium is borderline or vitamin D is severely deficient
  • CBC if clinical picture suggests secondary osteoporosis

Montana has 54 Critical Access Hospitals, many of which offer outpatient lab draw and DEXA imaging without a specialist referral. LabCorp has patient service centers in Billings, Missoula, Great Falls, Bozeman, and Kalispell. Quest operates through affiliated draw sites in several smaller communities. A telehealth provider can order these labs as part of a pre-visit requisition so results are ready before the video appointment.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Measurement of serum calcium, phosphate, and creatinine should be obtained prior to initiating bisphosphonate therapy, and vitamin D status should be assessed and optimized." AACE 2020 Osteoporosis Guidelines via PubMed

How to Get a Fosamax Prescription Through Telehealth in Montana

The process is straightforward. Montana law places no additional telehealth-specific requirements on alendronate beyond the standard requirements that apply to any prescription medication. The prescriber must establish a valid patient-provider relationship through a real-time audio-video encounter, document an appropriate evaluation, and maintain a record accessible for continuity of care.

Step-by-step for Montana residents:

  1. Gather your records. Locate your most recent DEXA scan report, any prior osteoporosis prescriptions, and your lab results. If you had a fragility fracture, bring imaging or discharge summaries.
  2. Book a telehealth appointment. HealthRX and similar platforms schedule same-week or next-business-day consultations. Visits typically run 20 to 30 minutes for an initial osteoporosis evaluation.
  3. Complete the video visit. The provider reviews your fracture history, fall risk, medications, renal function, GI history, and DEXA results.
  4. Receive your prescription electronically. Montana pharmacies accept e-prescriptions. You choose your preferred local pharmacy or mail-order service.
  5. Fill and pick up. Most Montana retail pharmacies stock generic alendronate 70 mg. GoodRx pricing for a 4-tablet (one-month) supply runs approximately $11 to $18 at Billings or Missoula pharmacies, though prices vary.

Total time from booking to medication in hand: 3 to 7 business days for most Montana residents, assuming labs are already available. If you need new labs, add 5 to 10 business days for draw, processing, and result review.

Montana Pharmacy Options for Alendronate

Generic alendronate 70 mg weekly tablets are available at virtually every pharmacy chain and independent pharmacy in Montana. Brick-and-mortar options include Albertsons Pharmacy, Walmart Pharmacy, Walgreens, Rosauers, and hundreds of independent pharmacies across rural communities. Mail-order pharmacies such as Express Scripts, CVS Caremark, and Amazon Pharmacy ship to Montana addresses.

503A compounding pharmacies: Montana-licensed 503A compounding pharmacies may prepare customized formulations of alendronate for patients with documented intolerances or specific clinical needs (for example, a liquid formulation for a patient who cannot swallow tablets). 503A pharmacies dispense pursuant to a valid individual patient prescription and are regulated by the Montana Board of Pharmacy. They are distinct from 503B outsourcing facilities, which produce bulk sterile preparations. Compounded alendronate is not bioequivalent-tested and should be considered only when commercial product is medically unsuitable.

A 2021 systematic review in Osteoporosis International confirmed that weekly alendronate 70 mg produces equivalent bone mineral density gains and equivalent fracture reduction to daily 10 mg dosing, with improved gastrointestinal tolerability. Osteoporosis International via PubMed The weekly formulation is therefore the standard dispensed at essentially every Montana pharmacy.

Insurance, Cost, and Prior Authorization in Montana

Commercial insurance: Most commercial plans in Montana cover generic alendronate with a Tier 1 or Tier 2 copay, typically $5 to $30 per month after deductible. Brand-name Fosamax carries a higher copay and is rarely medically necessary given bioequivalent generics.

Montana Medicaid: As of the date of this article, Montana Medicaid does not cover alendronate for the standard osteoporosis indication under most managed care contracts. Patients on Medicaid should ask their prescriber about prior authorization pathways, step therapy exemptions, or alternative covered agents such as risedronate (which does have some Medicaid coverage in Montana). The Montana Department of Public Health and Human Services updates its preferred drug list periodically.

Medicare Part D: Medicare Part D plans vary, but generic alendronate appears on the formulary of the majority of Montana-available Part D plans at low cost-sharing. Patients should use the Medicare Plan Finder tool to confirm their specific plan.

Prior authorization documentation: When a plan requires prior authorization, the prescriber typically submits:

  • DEXA T-score documentation
  • FRAX score calculation
  • Evidence of a fragility fracture (if applicable)
  • Confirmation of adequate calcium and vitamin D supplementation
  • Attestation that contraindications are absent

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) specifies that prior authorization processes should not delay initiation of therapy in patients with acute vertebral or hip fractures. BHOF Clinical Practice Guidelines via PubMed

Transferring an Existing Fosamax Prescription to Montana

If you relocate to Montana with an existing alendronate prescription from another state, you have two options.

Transfer to a Montana pharmacy: Because alendronate is a non-controlled substance, pharmacies in Montana can accept transfers from out-of-state pharmacies. Call your new preferred Montana pharmacy with the name and phone number of your previous pharmacy. Most transfers complete within 24 to 48 hours. The receiving pharmacy contacts the sending pharmacy directly to verify the remaining refills.

New prescription from a Montana-licensed provider: If your out-of-state prescription has no refills remaining or your original prescriber is no longer accessible, a telehealth visit with a Montana-licensed provider is the fastest path. The provider reviews your prior treatment history, confirms continued indication, and issues a new e-prescription.

One practical note: alendronate prescriptions are often written for one year (52 weeks, 52 tablets for the weekly formulation), with refills authorized annually. If you transfer a prescription with only a few refills left, schedule a follow-up evaluation before those refills expire. Annual DEXA monitoring is not universally required after therapy starts, but most guidelines recommend reassessing bone density at 1 to 2 years after initiation. National Osteoporosis Foundation guidelines via PubMed

How to Take Alendronate Correctly to Avoid Side Effects

The most common reason patients stop alendronate is upper GI discomfort, specifically esophageal irritation. The FDA label is explicit on administration requirements, and following them correctly reduces this risk substantially.

Correct administration:

  • Take the 70 mg tablet on the same day each week, first thing in the morning.
  • Swallow with a full 8-ounce (240 mL) glass of plain water only. No coffee, juice, mineral water, or other beverages.
  • Remain upright (sitting, standing, or walking) for at least 30 minutes after swallowing the tablet.
  • Do not eat, drink, or take other medications for at least 30 minutes after the dose.

Patients who report heartburn or reflux on alendronate may benefit from switching to risedronate (which has a slightly different GI profile) or, in appropriate cases, to an intravenous bisphosphonate such as zoledronic acid 5 mg once yearly. That decision requires a prescriber evaluation.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures are rare but recognized risks. ONJ incidence in patients taking oral bisphosphonates for osteoporosis (as opposed to oncologic doses) is estimated at 1 in 10,000 to 1 in 100,000 patient-years. ADA position statement via PubMed Atypical femoral fracture risk increases with duration of use beyond 5 years. Most guidelines recommend a drug holiday evaluation at 3 to 5 years in low-to-moderate risk patients and continuation in high-risk patients.

How Long Do You Take Alendronate

Most patients take alendronate for 3 to 5 years continuously, then undergo a formal reassessment. The American College of Rheumatology and the Bone Health and Osteoporosis Foundation both address drug holiday timing.

For patients who remain high-risk after 5 years (T-score still at or below -2.5, prior vertebral fracture, or ongoing glucocorticoid use), continued therapy or switching to a non-bisphosphonate agent such as denosumab is appropriate. For lower-risk patients whose bone density has stabilized, a drug holiday of 1 to 3 years may be offered, during which bone density is monitored annually.

An extension of FIT called FLEX (N=1,099) showed that women who discontinued alendronate after 5 years maintained bone mineral density without a statistically significant increase in non-vertebral fracture risk over the subsequent 5 years, though morphometric vertebral fracture risk was higher in those who stopped compared to those who continued. FLEX trial via PubMed That distinction matters clinically: radiographic vertebral fractures and clinically symptomatic fractures do not always overlap.

Monitoring After Starting Alendronate in Montana

Starting alendronate is the beginning of a long-term management plan, not a one-time prescription. Ongoing monitoring includes:

  • Repeat DEXA: At 1 to 2 years after starting therapy to confirm response, then every 2 years if stable.
  • Serum calcium and vitamin D: Annually, especially in patients with GI malabsorption or limited sun exposure (Montana winters are long and cold).
  • Renal function: Annual creatinine check is reasonable, as renal function can decline with age and alendronate requires dose adjustment or discontinuation when GFR <35.
  • Dental health: Inform your dentist that you are on a bisphosphonate before any invasive dental procedure.

Telehealth providers in Montana can order and interpret all of these follow-up labs remotely, making continuity of care feasible even for patients in Glacier County or Prairie County who may drive 90 minutes to reach a lab draw station.

Frequently asked questions

How do I get a Fosamax prescription in Montana?
You can get a Fosamax (alendronate) prescription from any Montana-licensed MD, DO, NP, or PA, either in person or through a telehealth video visit. You will need a DEXA scan showing a qualifying T-score, along with basic labs including serum calcium, creatinine, and 25-OH vitamin D. Telehealth platforms such as HealthRX can complete the evaluation and issue an e-prescription within days.
What labs are needed before Fosamax in Montana?
Your prescriber will require serum calcium, serum creatinine with an estimated GFR, and 25-hydroxyvitamin D before starting alendronate. A current DEXA scan (within 24 months) with T-scores at the lumbar spine and hip is also required to confirm the diagnosis. Additional labs such as PTH or CBC may be ordered if secondary osteoporosis is suspected.
Are there telehealth providers in Montana prescribing Fosamax?
Yes. Montana law (Montana Code Annotated 37-3-342) permits non-controlled medication prescribing through synchronous audio-video telehealth visits. Multiple platforms, including HealthRX, connect Montana patients with licensed providers who can evaluate osteoporosis, review DEXA results, and issue an alendronate prescription electronically to your preferred pharmacy.
How long until I receive Fosamax in Montana?
If your labs and DEXA scan are already available, the typical timeline is 3 to 7 business days: 1 to 2 days to book and complete a telehealth visit, 1 to 3 days for e-prescription processing and pharmacy fill. If new labs are needed first, add 5 to 10 business days for draw, processing, and result review before the prescribing visit.
Can I transfer a Fosamax prescription to Montana?
Yes. Alendronate is a non-controlled substance, so a Montana pharmacy can accept a transfer from any out-of-state pharmacy. Provide your new Montana pharmacy with the name and contact number of your previous pharmacy; transfers typically complete within 24 to 48 hours. If no refills remain, a telehealth visit with a Montana-licensed provider is the fastest path to a new prescription.
Are 503A pharmacies in Montana licensed to ship alendronate?
Yes. Montana-licensed 503A compounding pharmacies may prepare and dispense customized alendronate formulations (for example, a liquid form for patients who cannot swallow tablets) based on a valid individual patient prescription. They are regulated by the Montana Board of Pharmacy. Compounded alendronate is not bioequivalence-tested, so commercial generic tablets are preferred when the patient can tolerate them.
Who can prescribe Fosamax in Montana: MD, NP, or PA?
All three can prescribe alendronate in Montana. MDs and DOs have unrestricted prescriptive authority. Nurse practitioners in Montana have full practice authority and prescribe independently under Montana Code Annotated 37-8-202. Physician assistants prescribe under a delegation agreement with a supervising physician, a requirement most Montana PA practices already satisfy.
What documentation does prior authorization require in Montana?
Prior authorization for alendronate typically requires a DEXA scan report with T-scores, a FRAX 10-year fracture probability calculation, documentation of a prior fragility fracture if applicable, evidence that calcium and vitamin D supplementation are addressed, and confirmation that renal function is adequate (GFR at or above 35 mL/min/1.73m²). Your telehealth provider can prepare and submit this documentation to your insurer.

References

  1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-1541. PubMed
  2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082. PubMed
  3. FDA. Fosamax (alendronate sodium) Prescribing Information. Merck & Co., Inc. FDA label
  4. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020. Endocr Pract. 2020;26(Suppl 1):1-46. PubMed
  5. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049-2102. PubMed
  6. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). JAMA. 2006;296(24):2927-2938. PubMed
  7. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy. JADA. 2006;137(8):1144-1150. PubMed
  8. Khosla S, Cauley JA, Compston J, et al. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2017;32(3):424-430. PubMed
  9. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis. Rheumatol Int. 2009;30(2):213-221. PubMed